Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update

N. Lynn Henry(University of Michigan), Angela DeMichele(University of Pennsylvania), Beverly Moy(Massachusetts General Hospital), Kevin Kalinsky(Emory University), Erica Stringer-Reasor(University of Alabama at Birmingham), Lisa M. McShane(National Cancer Institute), Kelly M. Shanahan, Rebecca Shatsky(University of California San Diego), Priyanka Sharma(University of Kansas Medical Center), Melinda L. Telli(Stanford University), Mark R. Somerfield(American Society of Clinical Oncology), Nicholas C. Turner(Royal Marsden NHS Foundation Trust), Ben Ho Park(Vanderbilt University Medical Center), Anthony Elias(University of Colorado Cancer Center), Zoneddy Dayao(University of New Mexico Hospital)
Journal of Clinical Oncology
June 27, 2022
10.1200/jco.22.01063
Cited by 127

Related Papers

The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k